|
시장보고서
상품코드
2075906
신경 퇴행성 질환 시장 : 적응증별, 약제 유형별 및 지역별Neurodegenerative Disease Market, By Indication Type, By Drug Type, and By Geography - |
||||||
신경 퇴행성 질환 치료 시장은 2026년에 466억 5,310만 달러 규모에 이를 것으로 추정되며, 2033년까지 588억 7,570만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 3.4%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 466억 5,310만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 3.40% | 시장 규모 예측(2033년) : | 588억 7,570만 달러 |
신경 퇴행성 질환이란, 중추신경계의 세포가 기능을 상실하거나 사멸하는 질환의 일종입니다. 신경 퇴행성 질환은 '신경퇴행'이라고 불리는 과정에서 뉴런의 구조와 기능이 서서히 상실됨으로써 발생합니다. 알츠하이머병과 파킨슨병은 가장 흔한 신경 퇴행성 질환입니다. 신경 퇴행성 질환은 일반적으로 시간이 지남에 따라 악화되며, 완치할 방법은 없습니다.
시장 역학 :
신경 퇴행성 질환의 유병률 증가, 고령 인구 증가, 안전하고 효과적인 치료제에 대한 수요 증가, 신경 퇴행성 질환 및 이용 가능한 치료제에 대한 대중의 인식 제고, 그리고 탄탄한 제품 파이프라인이 예측 기간 동안 세계 신경 퇴행성 질환 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다.
예를 들어, 2022년 10월, Cyclo Therapeutics사는 초기 알츠하이머병 치료를 목적으로 아밀로이드 베타 및 타우 단백질의 감소를 표적으로 하는 임상시험용 신약 'Trappsol Cyclo'의 2b상 임상시험을 시작한다고 발표했습니다.
또한, 2022년 8월에는 Amneal Pharmaceuticals사가 파킨슨병 치료를 목적으로 한 카르비도파/레보도파 서방형 캡슐의 새로운 경구 제제인 'IPX203'에 대해 미국 식품의약국(FDA)에 신약 승인 신청서를 제출했습니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 세계 신경 퇴행성 질환 시장의 주요 기업 프로파일을 소개했습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 세계의 신경 퇴행성 질환 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 신경 퇴행성 질환 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 신경 퇴행성 질환 시장 : 적응증 유형별(2021-2033년)
제5장 세계의 신경 퇴행성 질환 시장 : 약제 유형별(2021-2033년)
제6장 세계의 신경 퇴행성 질환 시장 : 지역별(2021-2033년)
제7장 경쟁 구도
제8장 섹션
AJY 26.07.09Neurodegenerative Disease Treatment Market is estimated to be valued at USD 46,653.1 Mn in 2026 and is expected to reach USD 58,875.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 46,653.1 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.40% | 2033 Value Projection: | USD 58,875.7 Mn |
Neurodegenerative disease is a type of disease in which cells of the central nervous system stop working or die. Neurodegenerative disease is caused by the progressive loss of structure or function of neurons, in a process known as neurodegeneration. Alzheimer's disease and Parkinson's disease are the most common neurodegenerative diseases. Neurodegenerative disorders usually get worse over time and have no cure.
Market Dynamics:
Rise in prevalence of neurodegenerative diseases, growing geriatric population, rise in demand for safe and effective therapeutics, increasing public awareness about neurodegenerative disease and available therapeutics, and strong product pipeline are major factors expected to propel growth of the global neurodegenerative disease market over the forecast period.
For instance, in October 2022, Cyclo Therapeutics announced the launch of a Phase 2b study for its investigational drug, named Trappsol Cyclo, which targets the reduction of amyloid beta and tau to treat early Alzheimer's disease.
Moreover, in August 2022, Amneal Pharmaceuticals submitted a New Drug Application to the Food & Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa extended-release capsules for the treatment of Parkinson's disease.
Key Features of the Study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global neurodegenerative disease market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Amneal Pharmaceuticals Inc., Boehringer Ingelheim International Gmbh, F. Hoffmann-La Roche, Abbvie Inc., and Merck & Co. Inc., among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global neurodegenerative disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurodegenerative disease market.
Detailed Segmentation:
- Global Neurodegenerative Disease Market, By Indication Type (Revenue, USD Mn, 2021 - 2033)
- Parkinson's Disease
- Alzheimer's Disease
- Multiple Sclerosis
- Huntington Disease
- Other Indication Types
- Global Neurodegenerative Disease Market, By Drug Type (Revenue, USD Mn, 2021 - 2033)
- N-methyl-D-aspartate Receptor antagonists
- Cholinesterase Inhibitors
- Dopamine Agonists
- Immunomodulatory Drugs
- Other Drug Types
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Abbvie Inc.
- Amneal Pharmaceuticals Inc.
- Boehringer Ingelheim International Gmbh
- Hoffmann-La Roche
- Merck & Co. Inc.
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Indication Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rise in prevalence of neurodegenerative diseases
- Stringent regulatory guidelines
- Increase in demand for novel therapeutics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Neurodegenerative Disease Market, By Indication Type, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Parkinson's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Alzheimer's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Multiple Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Huntington Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Other Indication Types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
5. Global Neurodegenerative Disease Market, By Drug Type, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- N-methyl-D-aspartate Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Cholinesterase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Dopamine Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Immunomodulatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Other Drug Types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
6. Global Neurodegenerative Disease Market, By Geography, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Rest of World
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
7. Competitive Landscape
- Abbvie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amneal Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim International Gmbh
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-La Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co. Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
8. Section
- Research Methodology
- About us
